Nordic Capital Fund IX agreed to acquire a majority holding in Orchid Orthopedic Solutions from Altor Fund III, which will retain a significant minority holding. Orchid’s current management team will remain in place.
Orchid provides contract design and manufacturing services from concept through launch, serving its global customer base from 12 manufacturing sites in the U.S., U.K., Switzerland and China. Markets include joint reconstruction, spine, trauma, sports medicine, extremities, dental and cardiovascular.
The company has undertaken a vast number of M&A transactions since its formation in 2005, increasing its capabilities and reach. Altor purchased the company, which was previously backed by Churchill Equity Partners, in 2011.
ORTHOWORLD estimates place Orchid's annual orthopaedic-related revenue in the range of $315MM to $325MM, holding 6% of an over $5BB global orthopaedic contract manufacturing market.
Sources: Orchid Orthopedic Solutions; ORTHOWORLD estimates